Comment on

• Tolvaptan in patients with autosomal dominant polycystic kidney disease.

  Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
• Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

  Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators. Torres VE, et al. Nephrol Dial Transplant. 2017 Jul 1;32(7):1262. doi: 10.1093/ndt/gfx079. Nephrol Dial Transplant. 2017. PMID: 28444221 No abstract available.
• Tumor necrosis factor superfamily member (TNFSF) 13 (APRIL) and TNFSF13B (BAFF) downregulate homeostatic immunoglobulin production in the intestines.

  Hashiguchi M, Kashiwakura Y, Kanno Y, Kojima H, Kobata T. Hashiguchi M, et al. Cell Immunol. 2018 Jan;323:41-48. doi: 10.1016/j.cellimm.2017.10.009. Epub 2017 Oct 27. Cell Immunol. 2018. PMID: 29100594
• Doubts about the efficacy of tolvaptan for polycystic kidney disease.

  Anderson CL. Anderson CL. Clin Nephrol. 2020 Jun;93(6):307-309. doi: 10.5414/CN109927Letter. Clin Nephrol. 2020. PMID: 32000887 No abstract available.